Ananda Developments

Home

Announcements

Updates

Investment Opportunity

Corporate Governance

Company and Advisors

Publications

Broker Coverage

Directors

Shareholders

New investors

Ubuntu

We are pleased to announce that MRX1, one of our CBD drug candidates has successfully passed through a number of critical drug stability timepoints ahead of its use in two Phase II and one Phase I clinical studies.

The term ‘drug stability’ refers to the extent to which a drug retains, within specified time limits throughout its period of storage and use, acceptably comparable properties and characteristics to that which it possessed at the time of manufacture.

Link to info on the clinical trials mentioned in the video: https://investors.anandadevelopments.com/s/575042